Skip to main content
Premium Trial:

Request an Annual Quote

Rainer Lichtenberger, Stefan Kochanek

Premium
Cevec Pharmaceuticals this week announced the appointment of Rainer Lichtenberger as CEO, replacing Stefan Kochanek, a founder of the company, who had served as interim CEO.
 
Lichtenberg most recently was CEO of German biopharmaceutical development company Neuraxo Biotec. He also has held various positions, including vice president of strategic marketing and corporate vice president of business development at the Merckle/ratiopharm group and Merck.
 
Kochanek will continue to serve as a board member.
 
Cevec, based in Cologne, Germany, develops therapeutic proteins and monoclonal antibodies with human glycosylation patterns.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.